PTPRC and B-cell chronic lymphocytic leukemia: Inhibiting CD38 receptor or enzymatic activities reduced CD43 expression and galectin-1 binding, highlighting the potential of targeting the CD38/CD45 molecular hub as a therapeutic strategy in CLL.